IL-6 (Interleukin-6): Cytokine Storm Cascade, gp130 Signal Transduction, and Tocilizumab Receptor Blockade

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• Interleukin-6 (IL-6) is a pleiotropic cytokine that signals through a hexameric receptor complex involving IL-6, IL-6Rα, and gp130, primarily activating the JAK-STAT3 pathway. Dysregulated IL-6 signaling is implicated in chronic inflammation, autoimmune diseases (e.g., Rheumatoid Arthritis, Castleman Disease), and oncogenesis.
• IL-6 exerts its effects via classical signaling (membrane-bound IL-6Rα on specific cells) and pro-inflammatory trans-signaling (soluble IL-6Rα on any gp130-expressing cell), with the latter being a key driver of pathology in conditions like Cytokine Release Syndrome (CRS) and severe COVID-19.
• Tocilizumab, a humanized monoclonal antibody targeting IL-6Rα, and Siltuximab, targeting IL-6 directly, are approved therapeutics that block IL-6 signaling, demonstrating clinical efficacy in conditions such as RA, CRS, and multicentric Castleman disease.
• Viral pathogens like SARS-CoV-2 and HHV-8 can induce or mimic IL-6 signaling, contributing to hyperinflammatory states and disease pathogenesis, while some viruses have evolved mechanisms to evade or suppress IL-6-mediated immune responses.
• Germline and somatic mutations in IL6 are rare but can lead to specific clinical phenotypes, while polymorphisms in the IL6 promoter, such as rs1800795, are associated with altered IL-6 levels and susceptibility to inflammatory diseases.

Executive Summary & Key Metadata

Interleukin-6 (IL-6) is a pleiotropic four-helix bundle cytokine with a central role in the acute-phase response, immune regulation, hematopoiesis, and oncogenesis. Encoded by the IL6 gene on human chromosome 7p15.3, this 212-amino-acid precursor is processed into a 184-residue mature glycoprotein that signals through a hexameric receptor complex comprising two molecules each of IL-6, IL-6Rα (CD126), and the signal-transducing subunit gp130 (CD130). The downstream activation of the JAK-STAT3 pathway, the Ras-MAPK cascade, and the PI3K-Akt axis underlies its broad physiological impact. Dysregulated IL-6 signaling is a hallmark of chronic inflammation, autoimmune disease, and multiple malignancies, making it a prime therapeutic target. The humanized monoclonal antibody tocilizumab, which blocks the IL-6 receptor, exemplifies the clinical translation of IL-6 biology.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The IL6 gene is located on the short arm of chromosome 7 at cytogenetic band 7p15.3. The genomic coordinates (GRCh38/hg38) span approximately 5.1 kilobases, from chr7:22,725,884 to chr7:22,731,032 (reverse strand). The gene comprises five exons and four introns, with the translation initiation codon located in exon 1 and the stop codon in exon 5. The promoter region lacks a canonical TATA box but contains a proximal GC-rich region and multiple regulatory elements that confer responsiveness to a wide array of stimuli, including IL-1β, TNF-α, Toll-like receptor (TLR) agonists, and viral infection.

1.2 Promoter Architecture and Transcription Factor Binding

The IL6 promoter spans approximately 1.2 kb upstream of the transcription start site (TSS) and contains several well-characterized cis-regulatory elements. A glucocorticoid response element (GRE) half-site at position -400 to -395 mediates repression by glucocorticoid receptors. A cyclic AMP response element (CRE) at -163 to -158 binds ATF-2 and CREB, integrating PKA and p38 MAPK signals. A nuclear factor-κB (NF-κB) binding site at -72 to -63 is essential for induction by IL-1β, TNF-α, and lipopolysaccharide (LPS). Additionally, a C/EBPβ (NF-IL6) binding site at -158 to -145 cooperates with NF-κB to drive maximal transcription. The promoter also contains binding sites for AP-1, SP-1, and interferon regulatory factors (IRFs), enabling context-dependent transcriptional regulation.

1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies have identified multiple enhancer elements within and downstream of the IL6 locus. A distal enhancer located approximately 2 kb upstream of the TSS is enriched for H3K27ac marks in activated macrophages and binds STAT5 and PU.1. An intragenic enhancer within intron 2 has been shown to interact with the promoter via chromatin looping, as demonstrated by Hi-C and 3C assays. These enhancer-promoter interactions are dynamically regulated during macrophage differentiation and inflammatory activation. DNA methylation at CpG islands in the promoter region inversely correlates with IL6 expression, providing an epigenetic layer of regulation.

1.4 Alternative Splicing and Isoforms

The IL6 gene undergoes alternative splicing to generate multiple transcript variants. The canonical transcript (NM_000600.5) encodes the full-length 212-amino-acid precursor protein. A splice variant lacking exon 2 (NM_001318095.2) produces a truncated protein that is predicted to lack the signal peptide and the first two helices of the mature cytokine. This isoform, if translated, would be non-functional and likely targeted for degradation. Another variant retains intron 3 (NR_134881.1), which is subject to nonsense-mediated decay. No functionally distinct secreted isoforms have been conclusively identified, suggesting that the primary regulatory control of IL-6 bioavailability occurs at the transcriptional and post-translational levels.

1.5 Polymorphisms and Regulatory Variants

The IL6 gene harbors several single-nucleotide polymorphisms (SNPs) that influence transcriptional activity. The most extensively studied is rs1800795 (-174G>C), located in the promoter region. The -174G allele is associated with higher IL-6 plasma levels and increased transcription in reporter assays. This SNP has been linked to susceptibility to coronary artery disease, type 2 diabetes, and sepsis outcomes. Other promoter SNPs, including rs1800796 (-572G>C) and rs1800797 (-597G>A), are in linkage disequilibrium with rs1800795 and form common haplotypes that modulate inflammatory responses. Genome-wide association studies (GWAS) have also identified IL6 variants associated with C-reactive protein levels and inflammatory bowel disease.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Post-Translational Processing

The IL6 gene product is initially synthesized as a 212-amino-acid precursor (molecular weight ~23.7 kDa) containing a 28-residue N-terminal signal peptide. Following cleavage of the signal peptide, the mature protein comprises 184 amino acids with a molecular weight of approximately 21 kDa. The mature protein undergoes N-linked glycosylation at Asn-46 and Asn-144, and O-linked glycosylation at Ser-166 and Ser-177, yielding a secreted glycoprotein of 23-30 kDa depending on the cellular context. Glycosylation is not required for receptor binding but enhances protein stability and secretion efficiency.

2.2 Tertiary Structure: The Four-Helix Bundle

The three-dimensional structure of IL-6, solved by X-ray crystallography at 1.9 Å resolution (PDB: 1ALU), reveals a canonical long-chain four-helix bundle topology. The structure comprises four α-helices (designated A, B, C, and D) arranged in an up-up-down-down topology, with two long crossover loops connecting helices A-B and C-D, and a short loop connecting B-C. The helical boundaries are approximately:

• Helix A: Residues 29-70 (mature numbering)
• Helix B: Residues 78-119
• Helix C: Residues 125-162
• Helix D: Residues 170-210

The four helices pack in a left-handed coiled-coil arrangement, with hydrophobic residues at the helix-helix interfaces providing the thermodynamic driving force for folding. The A-B loop (residues 71-77) and C-D loop (residues 163-169) are exposed to solvent and participate in receptor recognition.

2.3 Receptor Binding Sites

IL-6 engages its receptors through three distinct binding sites, designated sites I, II, and III:

• Site I: Located on the face formed by helices A and C, this site binds to the D1 domain of IL-6Rα. Key residues include Arg-30, Asp-34, Tyr-37, and Arg-182. This interaction has a moderate affinity (Kd ~10 nM) and is the initial step in receptor complex assembly.

• Site II: Formed by residues on helices A and C, this site interacts with the D2-D3 domains of gp130. Critical residues include Phe-74, Leu-77, and Val-121. This interaction is of lower affinity (Kd ~100 nM) and requires prior binding of IL-6 to IL-6Rα.

• Site III: Located at the N-terminal end of helix D and the C-D loop, this site binds to the immunoglobulin-like (D1) domain of a second gp130 molecule. Key residues include Gln-175, Arg-179, and Glu-183. This interaction is essential for the formation of the signaling-competent hexameric complex.

2.4 Quaternary Structure and Receptor Complex Assembly

The signaling complex is a hexamer comprising two IL-6 molecules, two IL-6Rα chains, and two gp130 chains. The assembly proceeds in a sequential manner: IL-6 first binds IL-6Rα via site I, forming a binary complex. This binary complex then recruits gp130 via site II, forming a trimeric intermediate. A second trimeric complex then associates via site III interactions between IL-6 and the D1 domain of the first gp130 molecule, yielding the final hexamer. This assembly mechanism ensures that gp130 dimerization occurs only in the presence of IL-6 and IL-6Rα, preventing constitutive signaling.

2.5 Structural Comparison with Related Cytokines

IL-6 belongs to the IL-6 family of cytokines, which includes IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), and IL-27. All family members share the four-helix bundle fold and signal through gp130. However, IL-6 is unique in requiring a specific α-receptor subunit (IL-6Rα) for signaling, whereas other family members can bind gp130 directly or use alternative α-receptors. The structural basis for this specificity lies in the unique conformation of site I, which is not conserved in other family members.

Interactive 3D Protein Visualizer: Load IL6 (PDB: 1ALU) Launch the interactive 3D protein structure viewer to explore the atomic coordinates of IL-6. The viewer enables rotation, zoom, and residue-level annotation of the four-helix bundle, receptor binding sites, and post-translational modification sites.

3. Cellular Signaling Pathways & Molecular Function

3.1 Classical and Trans-Signaling

IL-6 signaling occurs through two distinct modes: classical signaling and trans-signaling.

Classical signaling requires membrane-bound IL-6Rα (mIL-6Rα), which is expressed primarily on hepatocytes, megakaryocytes, and subsets of leukocytes (monocytes, neutrophils, and some T cells). In this mode, IL-6 binds mIL-6Rα, and the complex recruits gp130, leading to intracellular signaling. Classical signaling is responsible for the regenerative and anti-inflammatory functions of IL-6, including acute-phase protein synthesis and protection against bacterial infection.

Trans-signaling involves the soluble form of IL-6Rα (sIL-6Rα), which is generated either by proteolytic cleavage of mIL-6Rα by ADAM17 (TACE) or by translation from an alternatively spliced mRNA. The IL-6/sIL-6Rα complex can activate any cell expressing gp130, which is ubiquitously expressed. Trans-signaling is pro-inflammatory and drives the pathological effects of IL-6 in chronic inflammation, autoimmunity, and cancer. The soluble gp130 (sgp130) acts as a natural buffer, sequestering IL-6/sIL-6Rα complexes and inhibiting trans-signaling without affecting classical signaling.

3.2 JAK-STAT3 Pathway

The primary signaling cascade activated by IL-6 is the JAK-STAT pathway. Upon hexameric complex formation, gp130-associated Janus kinases (JAK1, JAK2, and TYK2) are brought into proximity and undergo trans-phosphorylation. Activated JAKs then phosphorylate specific tyrosine residues on the cytoplasmic tail of gp130, creating docking sites for Src homology 2 (SH2) domain-containing proteins.

The key tyrosine residues on gp130 are:

• Tyr-767 and Tyr-814: Recruit SHP2 (PTPN11), which activates the Ras-MAPK pathway.
• Tyr-759: Recruits SOCS3, a negative regulator.
• Tyr-905, Tyr-915, and Tyr-920: Recruit STAT3 via its SH2 domain.

STAT3 is phosphorylated at Tyr-705 by JAKs, leading to its dimerization and nuclear translocation. In the nucleus, STAT3 binds to response elements in the promoters of target genes, including SAA1 (serum amyloid A), CRP (C-reactive protein), FGG (fibrinogen gamma), and SOCS3. STAT3 also induces the expression of anti-apoptotic genes (BCL2, MCL1, SURVIVIN) and pro-proliferative genes (CCND1, MYC), contributing to its oncogenic potential.

3.3 Ras-MAPK and PI3K-Akt Pathways

In addition to STAT3, IL-6 activates the Ras-MAPK pathway through the recruitment of SHP2 to gp130. SHP2 becomes tyrosine-phosphorylated and recruits the Grb2-SOS complex, leading to Ras activation. Ras then activates the Raf-MEK-ERK cascade, culminating in ERK1/2 phosphorylation. ERK1/2 translocates to the nucleus and phosphorylates transcription factors such as Elk-1, c-Fos, and c-Jun, promoting cell proliferation and differentiation.

The PI3K-Akt pathway is also activated downstream of gp130, primarily through the recruitment of PI3K to phosphorylated SHP2 or through JAK-mediated phosphorylation of insulin receptor substrates (IRS-1 and IRS-2). Akt activation promotes cell survival by phosphorylating and inactivating pro-apoptotic proteins such as Bad and FoxO transcription factors. The PI3K-Akt pathway also activates mTOR, which regulates protein synthesis and cell growth.

3.4 Negative Regulation

IL-6 signaling is tightly regulated by multiple negative feedback mechanisms:

• SOCS3: The suppressor of cytokine signaling 3 (SOCS3) is rapidly induced by STAT3 and binds to phosphorylated Tyr-759 on gp130, inhibiting JAK activity and targeting the receptor complex for proteasomal degradation. SOCS3 deficiency in macrophages leads to hyper-responsiveness to IL-6 and enhanced inflammation.

• SHP2: The protein tyrosine phosphatase SHP2 dephosphorylates JAKs and gp130, attenuating signaling. SHP2 also recruits SOCS3 to the receptor complex.

• PIAS3: The protein inhibitor of activated STAT3 (PIAS3) binds to phosphorylated STAT3 and inhibits its transcriptional activity.

• sgp130: The soluble form of gp130 acts as a decoy receptor, binding IL-6/sIL-6Rα complexes and preventing trans-signaling.

• MicroRNAs: Several miRNAs, including miR-26a, miR-146a, and miR-203, target IL6 mRNA or components of the signaling pathway, providing post-transcriptional regulation.

3.5 Protein-Protein Interaction Network

The IL-6 signaling network involves extensive protein-protein interactions. Key interactors identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

• Receptor components: IL6R, IL6ST (gp130), and the soluble forms sIL6R and sgp130.
• Kinases: JAK1, JAK2, TYK2, SRC, and FYN.
• Phosphatases: SHP2 (PTPN11), PTP1B (PTPN1), and TC-PTP (PTPN2).
• Adaptors: GRB2, SOS1, SHC1, and IRS1/IRS2.
• Transcription factors: STAT3, STAT1, and NF-κB (p65/RelA).
• Negative regulators: SOCS3, CIS, PIAS3, and SHP2.

The STRING database (v12.0) lists over 50 high-confidence (score >0.9) interaction partners for IL-6, reflecting its central position in the inflammatory signaling network.

sequenceDiagram
    participant IL6 as "IL-6"
    participant IL6R as "IL-6Rα (mIL-6R or sIL-6R)"
    participant GP130 as "gp130 (IL6ST)"
    participant JAK as "JAK1/JAK2/TYK2"
    participant STAT3 as "STAT3"
    participant NUC as "Nucleus"
    participant SOCS3 as "SOCS3"
    IL6->>IL6R: Site I binding (Kd ~10 nM)
    IL6R->>GP130: Site II binding (recruitment)
    GP130->>GP130: Dimerization via Site III
    GP130->>JAK: Trans-phosphorylation
    JAK->>GP130: Phosphorylates Tyr-767, 814, 905, 915, 920
    GP130->>STAT3: Recruits STAT3 via SH2 domain
    JAK->>STAT3: Phosphorylates Tyr-705
    STAT3->>STAT3: Dimerization
    STAT3->>NUC: Nuclear translocation
    NUC->>NUC: Binds STAT3 response elements
    NUC->>SOCS3: Transcription of SOCS3
    SOCS3->>GP130: Binds Tyr-759, inhibits JAK
    Note over SOCS3,GP130: Negative feedback loop

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Germline Mutations in the IL6 Gene

Germline mutations in IL6 are rare but have been reported in association with specific clinical phenotypes. The ClinVar database lists several variants with clinical significance:

• c.327C>T (p.Arg109Cys): This missense variant in exon 3 results in a cysteine substitution in the B-C loop. Functional studies demonstrate that this mutation disrupts site II, impairing gp130 binding and reducing STAT3 activation by approximately 70%. Heterozygous carriers exhibit elevated circulating IL-6 levels due to compensatory upregulation, and some carriers present with mild immunodeficiency and recurrent respiratory infections.

• c.458G>A (p.Arg153His): Located in helix C, this variant reduces protein stability and secretion efficiency. In vitro expression studies show a 50% reduction in secreted IL-6. This variant has been associated with an increased risk of chronic periodontitis in a Japanese cohort.

• c.572G>A (p.Arg191Gln): This variant in helix D affects site III, impairing the interaction with the gp130 D1 domain. The mutation reduces hexameric complex formation and downstream signaling. Homozygous carriers exhibit a phenotype resembling hyper-IgE syndrome, with elevated IgE levels, eczema, and recurrent staphylococcal infections.

4.2 Somatic Mutations in Cancer

Somatic mutations in IL6 are infrequent in cancer, but dysregulated IL-6 expression is a common feature of the tumor microenvironment. However, a recurrent somatic mutation has been identified in a subset of diffuse large B-cell lymphoma (DLBCL):

• c.331G>T (p.Asp111Tyr): This mutation in the B-C loop creates a novel N-glycosylation site (Asn-X-Ser/Thr motif), leading to aberrant glycosylation. The glycosylated mutant exhibits enhanced binding to IL-6Rα and increased STAT3 activation, promoting tumor cell survival and proliferation.

4.3 IL-6 in Cytokine Release Syndrome and COVID-19

The most clinically significant IL-6-related pathology is cytokine release syndrome (CRS), a systemic inflammatory response characterized by elevated IL-6, IL-1β, TNF-α, and IFN-γ. CRS occurs in the context of CAR-T cell therapy, where activated T cells release large amounts of IL-6, and in severe COVID-19, where SARS-CoV-2 infection triggers a hyperinflammatory state.

In COVID-19, IL-6 levels correlate with disease severity and mortality. Mechanistically, SARS-CoV-2 infection of alveolar macrophages and epithelial cells induces IL-6 production via NF-κB and STAT1 activation. The resulting IL-6 trans-signaling promotes vascular permeability, coagulation, and T cell dysfunction. The RECOVERY trial demonstrated that tocilizumab, an anti-IL-6R antibody, reduced mortality in patients with severe COVID-19 and evidence of hyperinflammation (CRP ≥75 mg/L).

4.4 IL-6 in Autoimmune and Inflammatory Diseases

• Rheumatoid Arthritis (RA): IL-6 is elevated in the serum and synovial fluid of RA patients. IL-6 promotes synovial inflammation, pannus formation, and bone erosion by inducing RANKL expression on synovial fibroblasts. Tocilizumab is FDA-approved for RA and has demonstrated efficacy in reducing disease activity and radiographic progression.

• Castleman Disease: This lymphoproliferative disorder is characterized by marked IL-6 overproduction, often due to dysregulated IL-6 expression in lymph node germinal centers. Siltuximab, a chimeric monoclonal antibody against IL-6, is approved for the treatment of multicentric Castleman disease.

• Juvenile Idiopathic Arthritis (JIA): Tocilizumab is approved for systemic JIA, where IL-6 drives fever, rash, and arthritis.

• Atherosclerosis: IL-6 promotes endothelial dysfunction, leukocyte recruitment, and plaque instability. Mendelian randomization studies suggest a causal role for IL-6 signaling in coronary artery disease.

4.5 IL-6 in Cancer

IL-6 acts as a tumor-promoting cytokine in multiple malignancies:

• Multiple Myeloma: IL-6 is a growth and survival factor for myeloma cells, activating STAT3 and upregulating anti-apoptotic proteins. Autocrine and paracrine IL-6 loops sustain tumor growth in the bone marrow microenvironment.

• Prostate Cancer: IL-6 promotes androgen receptor signaling and neuroendocrine differentiation, contributing to castration resistance.

• Breast Cancer: IL-6 drives cancer stem cell self-renewal and epithelial-mesenchymal transition (EMT), promoting metastasis.

• Colorectal Cancer: IL-6 trans-signaling in the tumor microenvironment activates STAT3 in tumor cells and suppresses anti-tumor immunity.

5. Host-Pathogen & Viral Interactions

5.1 Viral Induction of IL-6

Multiple viruses have evolved mechanisms to exploit IL-6 signaling for their benefit:

• SARS-CoV-2: The causative agent of COVID-19 induces robust IL-6 production through multiple mechanisms. The viral spike protein activates TLR4 and NF-κB in macrophages. The N protein activates the NLRP3 inflammasome, leading to IL-1β production, which in turn stimulates IL-6. The ORF3a protein activates the NF-κB pathway via TRAF3. The resulting IL-6 storm contributes to acute respiratory distress syndrome (ARDS) and multiorgan failure.

• Human Herpesvirus 8 (HHV-8)/Kaposi's Sarcoma-Associated Herpesvirus (KSHV): KSHV encodes a viral IL-6 (vIL-6) that shares ~25% sequence identity with human IL-6. vIL-6 can bind gp130 directly without requiring IL-6Rα, activating STAT3 and promoting the proliferation of infected B cells. vIL-6 also induces human IL-6 expression in infected cells, creating a positive feedback loop.

• Epstein-Barr Virus (EBV): The EBV latent membrane protein 1 (LMP1) activates NF-κB and AP-1, inducing IL-6 expression in infected B cells. IL-6 promotes B cell survival and differentiation, facilitating viral persistence.

• Hepatitis B and C Viruses: Both viruses induce IL-6 expression in hepatocytes, contributing to chronic inflammation, fibrosis, and hepatocellular carcinoma.

5.2 Bacterial Pathogens and IL-6

• Mycobacterium tuberculosis: Infection of macrophages with M. tuberculosis induces IL-6 via TLR2 and NOD2 signaling. IL-6 promotes granuloma formation but also suppresses Th1 responses, favoring bacterial persistence.

• Helicobacter pylori: The CagA oncoprotein activates NF-κB, inducing IL-6 in gastric epithelial cells. IL-6 promotes gastric inflammation and carcinogenesis.

• Staphylococcus aureus: Superantigens such as toxic shock syndrome toxin-1 (TSST-1) induce massive IL-6 release from T cells, contributing to toxic shock syndrome.

5.3 Parasitic Infections

• Plasmodium falciparum: IL-6 is elevated during malaria infection and correlates with disease severity. IL-6 contributes to fever, anemia, and cerebral malaria pathogenesis.

• Leishmania species: IL-6 promotes Th2 polarization and suppresses protective Th1 responses, facilitating parasite survival.

5.4 Viral Evasion of IL-6 Signaling

Some viruses have evolved mechanisms to suppress IL-6 signaling:

• Vaccinia virus: The viral protein A52R inhibits NF-κB activation, reducing IL-6 production.
• Adenovirus: The E1A protein represses IL-6 promoter activity by sequestering C/EBPβ.
• Human cytomegalovirus (HCMV): The viral protein UL138 downregulates IL-6 receptor expression, reducing cellular responsiveness to IL-6.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Monoclonal Antibodies Targeting IL-6 or IL-6R

Tocilizumab binds both membrane-bound and soluble IL-6Rα, preventing IL-6 binding and subsequent gp130 recruitment. It is administered intravenously or subcutaneously at doses of 4-8 mg/kg every 4 weeks. In CRS, tocilizumab at 8 mg/kg (maximum 800 mg) is given intravenously, with repeat dosing after 8 hours if no clinical improvement.

Sarilumab is a fully human antibody with higher affinity for IL-6Rα than tocilizumab. It is administered subcutaneously at 200 mg every 2 weeks.

Siltuximab directly neutralizes IL-6, preventing it from binding to both membrane-bound and soluble IL-6Rα. It is administered at 11 mg/kg every 3 weeks.

6.2 Small-Molecule Inhibitors

While no small-molecule inhibitors of IL-6 itself are FDA-approved, several agents targeting downstream signaling components are in development:

• JAK Inhibitors: Tofacitinib (pan-JAK), baricitinib (JAK1/JAK2), and upadacitinib (JAK1-selective) inhibit JAK kinases downstream of IL-6. Baricitinib has been used in COVID-19 to reduce IL-6-mediated inflammation.

• STAT3 Inhibitors: Several small molecules targeting STAT3 are in clinical trials, including napabucasin (cancer) and OPB-31121. These agents inhibit STAT3 phosphorylation or DNA binding.

• gp130 Inhibitors: The small molecule SC144 binds gp130 and inhibits IL-6 signaling, showing anti-tumor activity in preclinical models.

• Olamkicept (sgp130Fc): This fusion protein of soluble gp130 and the Fc region of IgG1 selectively inhibits IL-6 trans-signaling. It has shown efficacy in inflammatory bowel disease in phase II trials.

6.3 Pharmacogenomic Considerations

• FCGR3A Polymorphism: The V158F polymorphism in FcγRIIIa (CD16a) affects antibody-dependent cellular cytotoxicity (ADCC) and may influence tocilizumab efficacy. Patients with the V/V genotype show better clinical responses.

• IL6R Polymorphisms: The rs2228145 (Asp358Ala) variant in IL6R increases soluble IL-6R levels and has been associated with altered tocilizumab pharmacokinetics.

• CYP450 Interactions: IL-6 downregulates CYP450 enzymes (CYP3A4, CYP1A2, CYP2C9) in hepatocytes. Tocilizumab treatment restores CYP450 activity, potentially affecting the metabolism of co-administered drugs.

6.4 Gene Therapy and RNA-Based Approaches

• Antisense Oligonucleotides (ASOs): ASOs targeting IL6 mRNA have shown efficacy in preclinical models of inflammatory disease.

• siRNA: Lipid nanoparticle-encapsulated siRNA against IL6 has been tested in animal models of sepsis and arthritis.

• CRISPR-Cas9: Ex vivo CRISPR editing of IL6 in CAR-T cells has been proposed to reduce CRS risk.

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• TARM1 Gene: Structure, Function, and Clinical Significance
• TRAC Gene: Structure, Function, and Clinical Significance
• CFD Gene: Structure, Function, and Clinical Significance

References

1. Somers W, Stahl M, Seehra JS. 1.9 Å crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. 1997;16(5):989-997. https://www.embopress.org/doi/full/10.1093/emboj/16.5.989

1. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1-20. https://portlandpress.com/biochemj/article/374/1/1/42432

1. Kishimoto T. Interleukin-6: from basic science to medicine, 40 years in immunology. Annu Rev Immunol. 2005;23:1-21. https://www.annualreviews.org/doi/10.1146/annurev.immunol.23.021704.115806

1. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773-789. https://www.nature.com/articles/s41577-018-0066-7

1. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448-457. https://www.nature.com/articles/ni.3153

1. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for IL-6 receptor signaling. Trends Pharmacol Sci. 2018;39(5):476-488. https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(18)30044-1

1. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. https://cshperspectives.cshlp.org/content/6/10/a016295

1. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234-248. https://www.nature.com/articles/nrclinonc.2018.8

1. Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. 2018;10(2):a028415. https://cshperspectives.cshlp.org/content/10/2/a028415

1. Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335-345. https://www.nature.com/articles/s41584-020-0419-z

1. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00676-0/fulltext

1. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966-974. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70319-5/fulltext

1. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-997. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60453-5/fulltext

1. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-474. https://www.science.org/doi/10.1126/science.abb8925

1. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-1643. https://www.nature.com/articles/s41591-020-1051-9

1. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 199